BMS Continues Immuno-Oncology Push via Deals with CytomX and Incyte
By Heather Cartwright
Pharma Deals Review: Vol 2014 Issue 6 (Table of Contents)
Published: 11 Jun-2014
DOI: 10.3833/pdr.v2014.i6.2041 ISSN: 1756-7874
Section: Research & Development
Fulltext:
Abstract
Continuing the high level of deal-making activity seen in the immuno-oncology sector thus far in 2014, Bristol-Myers Squibb (BMS) has formed separate deals with CytomX Therapeutics and Incyte...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS